2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow ropsacitinib: new trials by email Literature Review of ropsacitinib trials Research Report on ropsacitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD - Ulcerative Colitis | Phase 2 | Withdrawn | Pfizer | 2020-09-30 | 2020-12-17 | |
| A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa PF-06650833, PF-06700841, PF-06826647 - Acne Inversa | Phase 2 | Completed | Pfizer | 194 | 2019-12-02 | 2023-06-15 |
| A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis PF-06826647 or Placebo, PF-06826647 - Psoriasis | Phase 2 | Completed | Pfizer | 179 | 2019-06-27 | 2021-08-27 |
Colitis, Ulcerative (1) · Hidradenitis Suppurativa (1) · Psoriasis (1)
Pfizer (3)
United States (3) · Canada (2) · Australia (1) · Japan (1) · Poland (1)
2018 (1), 2019 (1)